EX-10.1 2 kala-20180630ex1013daa12.htm EX-10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Fourth Amendment to Exclusive License Agreement
Confidential Materials omitted and filed separately with the |
Securities and Exchange Commission. Double asterisks denote omissions. |
Fourth Amendment
to Exclusive License Agreement
This Fourth Amendment to Exclusive License Agreement (the “Fourth Amendment”) is entered into by and between The Xxxxx Xxxxxxx University, a Maryland corporation having an address at 0000 Xxxxxxx Xxxxxx, Xxxxx 000, Xxxxxxxxx, XX 00000 (“JHU”) and Kala Pharmaceuticals, Inc., a Delaware corporation having an address at 000 Xxxxxx Xxxxxx, Xxxxx 000, Xxxxxxx, XX 00000 (“Kala” or “Company”).
WHEREAS, Kala and JHU entered into an Exclusive License Agreement dated November 10, 2009 (JHU Agmt No. [**]), as amended by a First Amendment dated November 19, 2012 (the “First Amendment”), a Second Amendment effective May 22, 2014 (the “Second Amendment”), and a Third Amendment effective August 26, 2014 (the “Third Amendment”) (as so amended, the “Agreement”), pursuant to which JHU licensed certain patent rights and know-how to Kala and modified certain milestones and other terms of the Agreement, and Kala, Graybug Vision, Inc. (formerly known as GrayBug, LLC and GrayBug, Inc.) (“Graybug”) and JHU entered into a Settlement and License Agreement effective October 24, 2014 (JHU Agmt No. [**], hereinafter the “S&L Agreement”), to resolve a dispute over rights licensed to Kala and Graybug under certain JHU patent rights; and
WHEREAS, pursuant to the S&L Agreement, JHU co-licensed Kala and Graybug under all the patent rights arising from JHU Ref # [**] (“Other JHU Patent Rights”), granting Kala an exclusive, sublicensable, worldwide license in the field of use of a Particle for delivery of a biologically active material through mucus, mucin, or a mucosal barrier where such delivery does not involve administration via injection to the eye (“Kala Field”), and granting Graybug an exclusive, sublicensable, worldwide license in the field of use of a particle for delivery of a biologically active material to the eye via injection, excluding any particle comprising or consisting of loteprednol etabonate (“Graybug Field”); and
|
|
|
JHU/Kala Fourth Amendment |
|
Page 1 of 4 |
JHU Agmt Ref. No. [**] |
|
|
WHEREAS, the parties wish to amend the Agreement on the terms set forth herein;
1. |
2. |
3. |
4. |
Agreement Section 1.10. As of the Fourth Amendment Date, Section 1.10 of the Agreement shall be superseded in its entirety by the following: |
"PATENT RIGHTS" shall mean the issued patents and patent applications listed in EXHIBIT D for JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], and for KALA/JHU JOINTLY OWNED PATENT RIGHTS (JHU Ref # [**]) (all such patent applications for JHU Ref # [**], JHU Ref # [**], JHU Ref # [**],
JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref. # [**], JHU Ref # [**], JHU Ref # [**], and JHU Ref # [**] hereinafter referred to as “Patent Applications”) and all continuations, divisions, claims of continuations-in-part applications directed to subject matter specifically described in the Patent Applications, continued prosecution applications and reissues, reexaminations, extensions and supplemental protection certificates thereof, and any corresponding foreign patent applications, and any patents, or other equivalent foreign
|
|
|
JHU/Kala Fourth Amendment |
|
Page 2 of 4 |
JHU Agmt Ref. No. [**] |
|
|
patent rights issuing, granted or registered thereon. “OPTION PATENT RIGHTS” shall mean the patents and applications listed in EXHIBIT D for JHU Ref # [**] (hereinafter referred to as “Option Patent Applications”) and all continuations, divisions, claims of continuations-in-part applications directed to subject matter specifically described in the Option Patent Applications, continued prosecution applications and reissues, reexaminations, extensions and supplemental protection certificates thereof, and any corresponding foreign patent applications, and any patents, or other equivalent foreign patent rights issuing, granted or registered thereon. In the event of the exercise by Company of the option set forth in Section 2.5, the OPTION PATENT RIGHTS shall become PATENT RIGHTS for all purposes of this Agreement, except as set forth in Section 2.4.
5. |
· |
JHU Ref. # [**], entitled, [**] (“New PATENT RIGHTS”). |
· |
Other JHU Patent Rights: |
o |
JHU Ref # [**], entitled [**]; |
o |
JHU Ref # [**], entitled [**]; and |
o |
JHU Ref # [**], entitled [**]. |
6. |
7. |
8. |
Amendment & License Fee. Company shall pay to JHU [**] Dollars ($[**]) as an amendment and license fee (the “Fourth Amendment Fee”) within [**] days of the Fourth Amendment Date. JHU is not required to submit an invoice for the Fourth Amendment Fee, which shall not be credited against royalties or other fees. |
9. |
In all other respects the Agreement shall remain in full force and effect. |
10. |
|
|
|
JHU/Kala Fourth Amendment |
|
Page 3 of 4 |
JHU Agmt Ref. No. [**] |
|
|
intended to preserve the original graphic and pictorial appearance of this Fourth Amendment shall have the same effect as the physical delivery of a paper document bearing the original signatures. All facsimile or electronic copies of this Fourth Amendment will be deemed to be duplicate originals. This Fourth Amendment may be executed simultaneously in any number of counterparts, any one of which need not contain the signature of more than one Party, but all of which shall be deemed an original and all such counterparts taken together shall constitute one and the same instrument. |
|
|
|
|
|
THE XXXXX XXXXXXX UNIVERSITY |
|
KALA PHARMACEUTICALS, INC. | ||
|
|
|
|
|
By: |
/s/ Xxxxxx X. Xxxxxxxxx |
|
By: |
/s/ Xxxx X. Xxxxxxxxxxxx |
Name: |
Xxxxxx X. Xxxxxxxxx |
|
Name: |
Xxxx X. Xxxxxxxxxxxx |
Title: |
Sr Director – JHTV |
|
Title: |
General Counsel & Corporate Secretary |
|
|
|
|
|
Date: |
June 22, 2018 |
|
Date: |
June 22, 2018 |
|
|
|
|
|
|
|
|
JHU/Kala Fourth Amendment |
|
Page 4 of 4 |
JHU Agmt Ref. No. [**] |
|
|
EXHIBIT D
PATENT RIGHTS
[**]
|
|
|
|
|
|
|
Institution Number |
Application Number |
Type of Patent Filing |
Application Date |
Publication or Patent Number |
Publication or Grant Date |
Filing Country |
[**] |
[**] |
[**] |
[**] |
|
|
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
|
[**] |
[**] |
[**] |
[**] |
|
|
[**]
|
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
[**] |
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 8 pages were omitted. [**]
|
|
|
JHU/Kala Fourth Amendment |
|
Amended Exhibit D- Page 1 of 1 |
JHU Agmt Ref. No. [**] |
|
|